Research Study for Patients with Metastatic Renal Cell Carcinoma
This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.
- Life expectancy of at least 12 weeks - Clinical, radiographic, or pathologic diagnosis of metastatic renal cell carcinoma (RCC). All renal cell histologies are allowed- Acceptable surgical risk in the judgment of the study investigator and consulting urological surgeon - At least one uni-dimensional measurable lesion outside the planned nephrectomy specimen - Patients who have an ECOG performance status of 0 or 1
- History of bleeding diathesis or unexpected surgical bleeding- Patients currently receiving treatment with or having a requirement for therapeutic anticoagulation - Prior therapy for RCC. Palliative radiation therapy for painful or unstable bone metastases is permitted provided that there is measurable metastatic disease outside the radiation field - Known history of HIV infection- Symptomatic metastatic brain or meningeal tumors, unless the patient is > 6 months from definitive therapy, has a CT or MRI scan within 6 weeks of study entry negative for brain metastases and is clinically stable with respect to the tumor at the time of study entry
Dana-Farber Cancer Institute
Boston, United States, 02115-6084
E-mail: [email protected]
Phone: Not Available
A Phase II study of BAY 43-9006 prior to and following nephrectomy in patients with metastatic renal cell carcinoma.